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The development of antibody responses to complex antigens requires interactions 
among antigen-presenting macrophages (M~), 1 B cells, and helper T  cell populations 
that are regulated or restricted by products of the I region (usually the I-A subregion) 
of the murine  H-2 complex (1-8).  Although strict  genetic restrictions control M~- 
immune T  cell interactions in antibody and DNA synthetic responses to antigen (6- 
9), these restrictions were not apparent in primary plaque-forming cell (PFC) responses 
to the polymer of L-glutamic acidn°-L-alaninea°-L-tyrosine  x° (GAT; 6, 7, 10). Syngeneic 
or allogeneic Mth presented GAT with similar efficiency and stimulated comparable 
PFC responses, suggesting a lack of genetic restrictions in M@virgin T cell interactions. 
It is,  however, virtually impossible to exclude the involvement of allogeneic effects 
resulting  from  the  accompanying mixed  lymphocyte reaction  (MLR),  even  if not 
detectable  by  a  variety of criteria  (6),  in  responses  stimulated  by allogeneic Mth. 
Therefore,  we  attempted  to  induce  aUoantigen-specific  tolerance  by  injection  of 
semiallogeneic  cells  into  neonates  (11-14)  to  analyze  primary  responses  to  GAT 
stimulated  by allogeneic  Mth  in  the  absence  of potential  complications  involving 
alloreactivity. A problem with this approach is the difficulty of inducing tolerance to 
antigens encoded by the left half of the H-2 complex (H-2K to I-E region), the regions 
of interest in mice of the C57BL/10 genetic background, the strain of choice to allow 
future genetic mapping studies (13,  14). 
We  failed  to  induce  alloantigen  tolerance;  MLR  and  cytotoxic T  lymphocyte 
(CTL) responses were depressed but significant, and skin grafts were rejected normally. 
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We have, however, demonstrated a  population of suppressor T  cells  (Ts cells)  that is 
activated by I-A antigens of the haplotype encountered neonatally and that nonspe- 
cifically  suppresses  primary  PFC  responses  in  culture.  This  report  describes  some 
properties of these Ts cells and the genetic restrictions governing their activation and 
function, and discusses their possible significance. 
Materials  and Methods 
Mice.  C57BL/10  (B10),  B10.D2, B10.A, BALB/cAn, C3H/HeSn,  AKR/J,  and  (B10.D2 
X B 10)F1 mice were bred in the animal facility of  The Jewish Hospital, St. Louis, Mo. C3H.OL, 
B 10.GD, B 10.LG, B 10.A(4R), and B 10.A(5R)  mice were provided by Dr. D. Shreffler (Depart- 
ment of Genetics, Washington University School of Medicine, St. Louis, Mo.); B 10.A(3R)  mice 
were provided by Dr. J. Stimpfling (McLaughlin Research Institute, Great Falls, Mont.). Mice 
were maintained on water and laboratory chow ad libitum and used at 6-20 wk of age. 
Antigens.  GAT (~45,000 mol wt; Miles Laboratories Inc., Elkhart, Ind.) was prepared as 
previously described for use as antigen  in culture  (15),  preparing GAT-M~ (6), coupling to 
sheep erythrocytes (SRBC) for use as indicator cells in the hemolytic PFC assay (15), and for 
in  vivo immunization  (15).  Trinitrophenol  (TNP)-derivitized  sheep  and  horse erythrocytes 
(TNP-SRBC and TNP-HRBC) were prepared by the techniques of Rittenberg and Pratt (16) 
and used as antigen in culture or as indicator cells in the PFC assay. Keyhole limpet hemocyanin 
(KLH) and Brucella abortus (BA) were derivatized with TNP as described by Zitron et al.  (17). 
Immunizations.  Neonatal B10 or BALB/c mice received 20 X  106 syngeneic or (B10.D2 X 
BI0)F1 spleen cells in phosphate-buffered Ringer's solution, pH 7.6, via the orbital branch of 
the anterior facial vein within  18 h of birth, as described by Billingham et al.  (11,  12). Mice 
were  analyzed  for immune  reactivity  at  6-20  wk of age.  Adult  mice were  immunized  by 
intraperitoneal  injections  of  10 #g GAT in  a  mixture  of magnesium-aluminum  hydroxide 
(Maalox; W. H. Roher, Inc., Ft. Washington, Pa.) and pertussis vaccine (Eli Lilly, Indianapolis, 
6  6  Ind.;  15) or 4 X  10  of the appropriate GAT-M~ (bearing ~25 ng GAT/10  cells; 6). 
Preparation of Cell Populations.  T  cells were separated from single cell suspensions of lymph 
node or spleen  by  passage  over  nylon wool  columns  (18).  Peritoneal  exudate  cells  (PEC) 
obtained  by flushing  the  peritoneal  cavity of the  mice with  Hanks' balanced  salt  solution 
containing 10 IU/ml heparin were the source of M~. Spleen cells were treated with anti-Thy- 
1.2 serum and complement (C) and used as T celt-depleted spleen cells (t0). Spleen cells were 
irradiated as indicated using a Gamma-Cell 40 la7Cs source (Atomic Energy of Canada, Ltd., 
Ottawa, Canada). 
Culture System and Hemolytic Plaque Assay.  Spleen cells in completely supplemented  Eagle's 
minimal  essential  medium  with  10%  fetal  calf  serum  (lot  32301;  Reheis  Chemical  Co., 
Kankakee, Ill.)  were incubated with 3 ×  104 GAT-Mth, TNP-KLH-Mth, or soluble antigen as 
indicated at 5 ×  10  e cells in 0.6 ml in 16-mm wells of a 24-well tissue culture plate (FB-16-24- 
TC; Flow Laboratories, Inc., Linbro Chemical Co., Hamden, Conn.)  for 5 d under modified 
Mishell-Dutton conditions (19). GAT-MO were prepared using appropriate PEC as previously 
described (6) and had -2-4 ng CAT/105 cells. TNP-KLH-M~ were prepared by incubating 2 
×  10  e PEC with  100 #g/ml TNP-KLH in serum-free medium at 37°C for 60 min. Cells were 
washed, resuspended in medium, and added to culture. IgG GAT-specific, IgM and IgG anti- 
SRBC, or IgM and IgG TNP-specific PFC responses were assayed using the slide modification 
of the Jerne hemolytic plaque assay (19). Data are expressed as PFC/culture. In all experiments, 
neonatally treated mice were examined individually. 
MLR.  Spleen or lymph node cells (2.5 X 105) from responder mice were incubated with an 
equal  number of mitomycin C-treated  (50 #g/ml;  Sigma Chemical Co.,  St.  Louis, Mo.)  or 
irradiated  (2,000  tad)  stimulator  spleen  cells  from mice of appropriate  H-2  haplotypes  in 
5  RPMI-1640 supplemented with 2 mM L-glutamine, antibiotics, 5 ×  10-  M 2-mercaptoethanol, 
and 5% fetal calf serum  (Reheis Chemical Co.)  in 96-well  round-bottomed microtiter plates 
(Dynatech Laboratories Inc., Dynatech Corp., Alexandria, Vs.), in 0.2 ml in 5% CO2 in air. 
After 96  h,  each  well  received  1 #Ci  of tritiated  thymidine  ([SH]TdR;  6.7  Ci/mM  spac; 
Research Products International Corp., Elk Grove Village, Ill.)  and was harvested  18 h later 
using a  Titertek  Cell  Harvester  (Flow Laboratories,  Inc., Rockville,  Md.).  Incorporation of CRAIG M.  SORENSEN  AND CARL W.  PIERCE  37 
[aH]TdR  into  DNA  was  determined  in  a  Beckman  Scintillation Counter  (model  LS-333; 
Beckman Instruments Inc., Fullerton, Calif.). Data are presented as mean cpm incorporation 
in triplicate wells. 
CTL Responses.  Responder spleen cells (7 ×  106 cells) were incubated with irradiated (2,000 
rad) stimulator spleen cells (3 ×  106 cells) in 2 ml of supplemented RPMI-1640 containing 10% 
fetal calf serum in  16-mm wells of a  24-well Linbro plate in 5% CO2 in air for 5 d. At assay, 
cells were adjusted to appropriate viable cell concentrations and added to the appropriate 51Cr- 
labeled tumor target cells at the indicated effeetor to target (E:T) cell ratios. These mixtures 
were incubated in 96-well round-bottomed microtiter plates (Dynatech Laboratories, Inc.) for 
4 h at 37°C; supernates were harvested and the amount of 5XCr released was determined in a 
gamma spectrometer (Beckman Instruments, Inc.). Percent specific SlCr release was calculated 
as follows: 
experimental release -  spontaneous release 
percent release --  ×  100. 
total release -- spontaneous release 
Total release was counts released by 1% sodium dodecyl sulfate. 
Results 
Immune Responses by Spleen Cells from Neonatally  Treated Mice.  Spleen cells from adult 
B10  (H-2  b)  mice  injected  as  neonates  with  20  ×  10 n  syngeneic  B10  spleen  cells 
developed significant MLR  and CTL responses to allogeneic AKR  (H-2  k) and B 10.D2 
(H-2  d)  stimulator  cells  (Table  I,  Fig.  1).  Spleen  cells  from  adult  mice  injected  as 
neonates  with  20  ×  106  semiallogeneic  [B10.D2  ×  B10  (H-2  d  x  b)]F1  spleen  cells 
developed normal MLR  and CTL  responses to allogeneic AKR  cells and lower, but 
nevertheless significant, responses to B 10.D2 stimulator cells, the allogeneic haplotype 
encountered  neonatally  (Table  II,  Fig.  1).  This  reactivity to  H-2  d  stimulator  cells 
suggested that at best only partial tolerance had been induced. Complete unreactivity 
to H-2  d stimulator cells in MLR  and CTL responses could not be demonstrated under 
any conditions where the numbers of stimulator or responder cells or the time of assay 
were varied. Moreover, B10 mice treated as neonates with  (B10.D2  ×  B10)F1 spleen 
cells rejected first-set H-2  a skin grafts with the same kinetics, 16-17 d, as normal B10 
mice or B10  mice  treated with  syngeneic spleen  cells as neonates.  These  mice also 
failed to develop responses to H-2  a antigens in vivo, but  developed significant titers 
to H-2  k antigens.  An identical pattern of reactivity was observed in BALB/c  (H-2  d) 
mice treated as neonates with  (B10.D2  ×  B10)F1  spleen cells; these spleen cells had 
TABLE I 
MLR Responses by Spleen Cells  from Neonatally Treated Mice 
[nH]TdR incorporation  (cpm ~ SEM) 
Stimulator cells  responder cells 
B10c  Bl0t 
B10  4,400 (1.02)  4,100 (1.05) 
AKR  11,500 (1.11)  11,880 (1.06) 
B10.D2  14,300 (1.04)  8,200 (1.03) 
Spleen cells from adult B10 mice injected as neonates with B10 spleen cells 
(B10c) or (B10.D2 × B10)Fa spleen cells (B10t) were cultured at 2.5 ×  105 cells 
with an equal number of the indicated irradiated (2,000 rad) stimulator spleen 
cells. The cultures received 1 /zCi of [nH]TdR on day 3, were harvested  18 h 
later,  and  assayed  for  incorporation  of ~aH]TdR.  Data  are  expressed  as 
geometric mean cpm of triplicate cultures; ~  SEM are in parentheses. 38  HAPLOTYPE-SPECIFIC  SUPPRESSOR  T  CELLS 
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EFFECTOR : TARGET  CELL  RATIO 
FXG.  1.  CTL responses by spleen cells from neonatally treated mice. Control (panel A) or treated 
(panel B)  B10 spleen cells (7 ×  10  o) were cultured with 3 X  106 irradiated  (2,000  rad) stimulator 
spleen cells for 5  d, and percent specific SlCr release at  the indicated E:T  ratios on appropriate 
target cells was determined. 0, B10 stimulator cells, EL-4 target cells (H-2b);  II, AKR stimulator 
cells  (H-2k),  YAC-1  target  cells  (H-2k/d);  &,  B10.D2  stimulator  cells,  P815  target  cells  (H-2d). 
Spontaneous release: P815, (11%), YAC-1 (8%), EL-4 (31%). 
TABLE  II 
Prima~y In  Vitro PFC Responses by Spleen Cells  from Neonatally Treated 
Mice 
Antigens and M~ added 
Day 5 PFC/culture* 
BIO~  BlOt~ 
GAT  870  680 
B 10 GAT-M~  905  1,083 
AKR GAT-Mq~  675  618 
B10.D2 GAT-M~  663  <10 
(B10.D2 ×  B10)FI GAT-M~  698  <10 
SRBC  2,465  3,830 
SRBC +  AKR-Mdp  3,380  3,300 
SRBC +  B10.D2 Mq~  3,980  370 
* Spleen cells (5 x  10  n) were cultured under Mishell-Dutton conditions with 
2 pg soluble GAT, 3 X  104 GAT-Mq~ from the indicated strain bearing 3-4 
ng GAT 105 cells, l07 SRBC, or SRBC plus 3 X  104 MO from the indicated 
strain. IgG GAT-specific PFC/culture; IgM PFC/culture vs. SRBC. 
* B10e  indicates .B10  mice injected with B10  spleen cells as neonates;  B10t 
indicates B10 mice injected with (B10.D2 x  B10)F1 spleen cells as neonates. 
reduced,  but significant,  reactivity against  H-2  b stimulator cells in  MLR and CTL 
responses  and  the  mice  rejected  H-2  b  skin  grafts  normally.  Finally,  adult  B10  or 
BALB/c mice injected intraveously with 20 ×  10  e (B10.D2 x  B10)F1 spleen cells had 
enhanced  MLR  and  CTL responses when  stimulated  4  wk  later with  cells  of the 
allogeneic H-2  d haplotype used for injection  (data not shown). 
Spleen cells from B10 mice treated as neonates with (B10.D2 X B10)F1 spleen cells 
were also  tested  for their  ability  to  develop primary PFC  responses  in  vitro when 
stimulated with GAT presented on M~ of various H-2 haplotypes (Table II). Spleen 
cells from normal or control B10 mice developed significant responses to soluble GAT 
and to GAT-Mq~ from syngeneic B10 and allogeneic AKR and B10.D2 mice. Spleen 
cells  from  neonatally  treated  B10  mice  responded  to  soluble  GAT  and  to  GAT 
presented on syngeneic B 10 and unrelated allogeneic AKR-Mq~, but failed to respond 
to  BI0.D2  or  (B10.D2  ×  B10)F1  GAT-M~b.  Neonatally  treated  mice also  failed  to 
respond to SRBC in the presence of B 10.D2 M~ but responded at control levels in the CRAIG  M.  SORENSEN  AND  CARL  W.  PIERCE  39 
presence of allogeneic AKR M~. An identical pattern of responsiveness was observed 
in BALB/c spleen cells from mice treated as neonates with (B10.D2 ×  B10)F1 spleen 
cells; these spleen cells failed to respond to B 10 GAT-Mq~ but responded to BALB/c 
and AKR GAT-Mth and soluble GAT (data not shown). In all experiments, responses 
to SRBC in the absence of added syngeneic or allogeneic Mth were comparable. 
Demonstration of Haplotype-specific  Ts  Cells.  The role of active suppression  as  the 
basis  for the specific failure to respond to GAT-M~ of the H-2 haplotype that  the 
mice were exposed to as neonates was investigated. Spleen cells or T  cells from control 
or neonatally treated B10  mice were added  to normal  B10 spleen cells in cultures 
stimulated with GAT-Mth of various H-2 haplotypes (Table III). Control B10 spleen 
cells (experiment  1)  or T  cells (experiment 2)  did not alter the responses of normal 
B10 spleen cells to B10, AKR, or B10.D2 GAT-Mth. Spleen cells or T  cells from B10 
mice  injected  with  (B10.D2  ×  B10)F1  spleen  cells  as  neonates  did  not  alter  the 
responses of normal B 10 spleen cells to B 10 or AKR GAT-Mth; however, responses to 
B10.D2 GAT-Mth were completely suppressed. This degree of suppression was rou- 
tinely observed with 106 whole spleen cells or 0.5 X  106 T  cells from spleen or lymph 
node;  however,  thymocytes  (up  to  2  ×  106/culture)  from  treated  mice  failed  to 
TABLE III 
Suppression of PFC Responses by Cells  from Neonatally Treated Mice 
Experiment  GAT-Mq~ 
Day 5 IgG GAT-speeific PFC/ 
culture* 
Normal  Treated 
spleen  spleen 
cells:~  cells:~ 
1  B10  708  615 
AKR  510  600 
B10.D2  620  <10 
Normal  Treated 
T  cells  T  cells 
2  B 10  295  295 
AKR  360  310 
B10.D2  290  <10 
Treated spleen cells§ 
Control  aThy-  Irradi- 
1.2 +  C  ated 
3  B 10  550  655  633 
AKR  588  745  553 
B10.D2  <10  718  573 
* B10 spleen ceils, 5  ×  106, were cultured under Mishell-Dutton conditions 
with 3  ×  104 GAT-M~ from the indicated strain bearing 3-4 ng GAT  105 
cells.  Responses of B10 spleen cells stimulated with  the various GAT-Mq~ 
without  added  cells were comparable  to  the  responses in  the presence of 
normal spleen cells and normal T  cells. 
Spleen  cells (10n/culture);  nylon wool column-passed spleen cells  (T cells; 
0.5  ×  10n/culture).  Treated  cells from B10 mice injected  with  (B10.D2  X 
B 10)Fl spleen cells as neonates; normal cells were nontreated B 10 cells. 
§ Spleen cells from neonatally treated mice were untreated (control) or treated 
with anti-Thy-l.2 plus C  or with 350 rad before addition to culture. 40  HAPLOTYPE-SPECIFIC SUPPRESSOR T  CELLS 
suppress (data not shown). Analogous results have been obtained from BALB/c mice 
treated as  neonates with  (B10.D2  ×  B10)FI spleen cells when  B10 GAT-M~ were 
present in the assay cultures. Finally, the appropriate allogeneic M~ or the appropriate 
alloantigens on F1 M~ added to culture were sufficient to activate the suppressor cell 
(data not shown). Comparable viable cell recovery in all cultures suggested that the 
suppression was not the result of a selective cytotoxic mechanism. 
The activity of these suppressor cells was completely abrogated by treatment with 
anti-Thy-l.2 plus C  and  as little as  350 rad  gamma  irradiation  (Table III).  More 
complete characterization of these Ts cells will be the subject of a  future communi- 
cation. The addition of normal T  cells to spleen cells from neonatally treated mice, 
depleted ofT cells, restored the capacity to develop PFC responses to allogeneic GAT- 
Mq~ of the haplotype encountered as neonates. These results suggested that the B cell 
pool  was  intact  and  unaffected  by  the  neonatal  treatment  that  had  induced  a 
population of radiosensitive, haplotype-specific Ts cells. 
Parameters of Suppression by Haplotype-specific  Ts Cells.  These haplotype-specific Ts 
cells also  inhibited  primary  responses  to  SRBC,  and  anti-TNP  PFC  responses by 
normal syngeneic spleen cells to TNP-SRBC, TNP-KLH, TNP-FicolI, and TNP-BA. 
IgM PFC responses were suppressed, but to a  lesser extent than IgG responses, and 
responses  to  particulate  antigens  (TNP-SRBC,  SRBC,  and  TNP-BA)  were  more 
resistant  to suppression than responses to soluble antigens  (data not shown). These 
results demonstrated that these Ts cells inhibit IgM and IgG PFC responses to soluble 
and particulate, and T  cell-dependent and T  cell-dependent antigens (TNP-BA and 
TNP-FicoI1). 
The kinetics of suppression of primary PFC responses by haplotype-specific Ts cells 
was investigated under conditions in which the Ts cells were activated by adding the 
relevant Mq~ at various times after the initiation of cultures containing normal B10 
spleen cells and B10 spleen cells from neonatally treated mice (Table IV). Complete 
suppression of day 5  responses was observed only when the allogeneic B10.D2  Mq~ 
were added within 24 h of culture initiation. Suppression was significant but incom- 
plete when the Ts cells were activated at 36 h  and was more variable, ranging from 
0 to ~50%, when Ts cells were activated at 48 h. Higher numbers of Mq~ added at or 
after 48  h  were unable  to  activate Ts cells  to suppress  day  5  responses  (data  not 
shown). Ts cells, preactivated with the appropriate Mq~ for 48 h, failed to suppress 
PFC  responses completely when  added  to culture 48  h  after initiation,  but  when 
added  at  culture  initiation  or  24  h  after  culture  initiation,  the  Ts  cells  blocked 
initiation of the PFC responses. 
The ability of these haplotype-specific Ts cells to suppress secondary PFC responses 
to GAT was examined. Spleen cells from mice primed with syngeneic or allogeneic 
GAT-Mq~ developed secondary responses to GAT only when stimulated with GAT- 
Mq~ syngeneic to the Mq~ used for priming in vivo (6, 20). B10 mice were immunized 
with  B10,  B10.D2,  or  (B10.D2  ×  B10)F1  GAT-Mq~;  spleen  cells  from  these  mice 
developed secondary PFC responses only to the GAT-Mq~ syngeneic to those used for 
immunization (Table V). Ts cells from neonatally treated B 10 mice, which suppressed 
primary PFC responses when exposed to the appropriate allogeneic GAT-Mq~, failed 
to suppress secondary PFC responses to the same GAT-Mq~.  Thus, although these Ts 
cells can suppress PFC responses to a variety of antigens, only primary responses were CRAIG  M.  SORENSEN  AND  CARL W.  PIERCE  41 
TABLE  IV 
Kinetics of Suppression by Haplotype-specific Ts Cells 
Time of addi- 
tion of 
B10.D2 M~ 
Day 5 IgG GAT-specific 
PFC/culture 
Normal  Treated 
cells  cells 
Experiment 1 
Experiment 2 
h 
0  433  <10 
24  438  < 10 
36  405  125 
48  395  225 
Time of addi-  Normal  Treated 
tion of acti-  cells  cells 
vated Ts cells 
0  413  <10 
24  463  < 10 
48  400  278 
In experiment 1, 5 X 106 spleen cells were cultured with 10  n spleen cells from 
normal mice or B10 mice injected neonatally with (B10.D2 ×  B10)FI spleen 
cells and 2 #g GAT. At the indicated times, 3 ×  104 BI0.D2 PEC were added. 
In experiment 2, spleen cells from normal or neonatally treated B 10 mice were 
incubated with  3  ×  104  BI0.D2  PEC  for 48  h  and added as  indicated to 
cultures of 5 ×  l0  s normal B10 mice and 2 #g GAT. 
TABLE  V 
Haplotype-specific Ts Cells Are Unable to Suppress Secondary Responses to 
CAT 
GAT-M~ used for  T cells:~ 
priming* 
Day 5 IgG GAT-spe- 
cific PFC/culturc~ 
BI0  B10.D2 
GAT-M~  GAT-Mq~ 
None  Normal  840  715 
Treated  615  < 10 
B 10  Normal  740  < 10 
Treated  733  10 
B 10.D2  Normal  < 10  840 
Treated  < 10  778 
(BI0.D2  ×  B10)F~  Normal  903  783 
Treated  875  800 
* B10 mice were primed in vivo 4 wk before assay by intraperitoneal injection 
of 4  ×  106 GAT-Mq~ from the indicated strain bearing -25 ng GAT/106 
cells. 
:~ Nylon  wool  column-passed T  cells  from  normal  B10  mice or  B10  mice 
injected with (BI0.D2  ×  BI0)FI  spleen cells as neonates. 
§ B10 spleen cells, 5 ×  l0  s, cultured with 0.5 x  100 normal or treated B10 T 
cells and 3 ×  104 of the indicated GAT-M~ bearing 3-4 ng GAT/10  s cells. 
suppressed.  Moreover,  neonatally  treated  mice  cannot  be  primed  using  GAT-Mth 
against which the Ts cells are directed. 
Finally,  these haplotype-specific Ts  cells  were  unable  to  suppress either  CTL  or 
MLR  to the B10.D2  alloantigens (Table VI), although  the same Ts cells suppressed 42  HAPLOTYPE-SPECIFIC SUPPRESSOR  T  CELLS 
TABLE VI 
Haplotype-specific Ts Cells Are Unable to Suppress CTL and MLR Responses of Normal 
Spleen Cells 
Responder*  T cells* 
CTL response as- 
say, specific 51Cr  MLR assay, [SH]- 
release:}:  TdR incorpora- 
tion§ 
E:T ratio  P815 
B10c  None  20:1  90  3t,535  (1.05) 
5:1  74 
B10c  1.5 ×  106 control  20:1  90  34,897 (1.11) 
5:1  80 
B 10~  1.5 ×  106 treated  20:1  80  34,300 (1.08) 
5:1  63 
B10e  0.5 ×  106 treated  20:1  98  33,594 (1.06) 
5:1  75 
B10t  None  20:1  40  12,213 (1.05) 
5:1  15 
* B10c or control: B10 mice injected with B10 spleen cells as neonates. Bl0t or treated: spleen 
cells from mice injected with (B10.D2 × B10)Fx spleen cells as neonates. 
~: 7 ×  106 normal (B10c) or treated (B10t) spleen cells were cultured with 3 ×  106 irradiated 
(2,000 rad)  BI0.D2  stimulator spleen cells for 5 d with the indicated number of T cells 
from normal' or treated mice; percent specific 51Cr release at the indicated E:T cell ratios 
on P815 target cells was determined. Spontaneous release: P815 (9%). 
§ 200-/.d aliquot removed at 72 h and pulsed with 1 p.Ci [aH]TdR for 18 h. Data are presented 
as cpm ~ SEM. 
PFC responses in an independent assay when stimulated with B10.D2 cells. These Ts 
cells were also unable to suppress MLR  and CTL responses to AKR  stimulator cells, 
even in the presence of added B10.D2 cells to activate the Ts cells (data not shown). 
Thus,  these  Ts  cells were  unable  to  suppress  proliferation or cytotoxic lymphocyte 
responses by T  cells to alloantigens for which they were specific. 
Genetic Constraints  Governing Activity of Haplotype-specific  Ts Cells.  The subregion(s) of 
the H-2 complex responsible for the activation and restriction of activity of these Ts 
cells was  determined  using congenic  and  recombinant  strains  of mice  in  mapping 
studies. First, using Mq~ from  mice that shared regions of the H-2 complex with the 
allogeneic parent of the Fx cells administered to the neonates, the genetic requirements 
for activation of the Ts  cells were  determined  (Table VII).  B10.D2,  C3H.OL,  and 
B10.GD,  but  not  BI0.LG,  GAT-Mq~  activated  B10  Ts  cells  specific  for  the  H-2  d 
haplotype  resulting  in  suppression  of responses  by  normal  B10  spleen  cells.  Thus, 
syngenicity at the I-A subregion of the H-2 complex was necessary and sufficient for 
activation  of Ts  cells.  Second,  the  genetic  restrictions on  haplotype-specific Ts  cell 
activity were  determined using Ts  cells activated by the appropriate GAT-M~b and 
normal responder spleen cells that shared various regions of the H-2 complex (Table 
VIII). This analysis was potentially complicated because Ts cells and responding cells 
differ  at  some  regions  of  the  H-2  complex.  In  experiment  1,  responses  by  B10, 
B10.A(3R), and B10.A(5R)  spleen cells were suppressed by B10 Ts cells activated by 
the B 10.D2 Mq~, placing the restriction in the K, I-A, and I-B subregions and definitely 
eliminating  syngenicity  at  the  I-J  subregion  as  a  requirement  for  expression  of 
suppressive activity. The data in experiment 2  demonstrated that syngenicity at the 
I-A subregion of H-2 was necessary and sufficient for the Ts cells to express activity. CRAIG  M.  SORENSEN  AND  CARL  W.  PIERCE  43 
TABLE  VII 
Genetic Requirements for Activation of Haplotype-spec~c Ts Cells 
GAT-Mth*  Shared H-2 regions:~ 
Day 5 IgG GAT-spe- 
cific PFC/culture§ 
Control T  Treated T 
censll  cellsll 
B 10.D2  KABJECSGD  535  10 
B 10.A  CSGD  563  575 
C3H.OL  KABJEC  508  < 10 
B10.GD  KA  573  <10 
B 10.LG  K  500  488 
C3H  None  588  585 
* 3 ×  10  4 GAT-M~/culture bearing ~3-4 ng GAT/10  5 cells. 
:~H-2  regions  shared  between  the  stimulating GAT-M~  and  the  B10.D2 
haplotype for which the Ts cells are specific. 
§ B10 spleen cells, 5 X  10  6, were cultured with the indicated GAT-Mq} and 10  6 
control or neonatally treated B 10 T  cells under Mishell-Dutton conditions. 
[[ Control:  B10 mice injected with B10 spleen cells as neonates; treated:  B10 
mice injected with (B10.D2 X B10)Fx spleen cells as neonates. 
TA~X.E  VIII 
Genetic Restrictions on Haplotype-specific  Ts Cell Activity 
Experi-  Responder spleen  GAT-Mq~*  Shared H-2 regions~ 
ment  cells 
Day 5 IgG GAT- 
specific PFC/ 
culture~ 
Control  Treated 
T  cellsll  T  censll 
1  B10  B10.D2  KABJECSGD  448  <10 
B10.A(4R)  B10.D2  BJECSGD  348  390 
B10.A(3R)  BI0.D2  KABJ  440  <10 
B10.A(5R)  B10.D2  KAB  335  <10 
2  B 10.D2  B 10  KABJECSGD  485  < 10 
B 10.GD  B 10  KA  470  < 10 
B 10.LG  B 10  K  503  545 
* 3 ×  10' GAT-Mq~/culture bearing ~3-4 ng/10  5 cells. 
:~ H-2 regions shared between the T  cells and the responder spleen cells. 
§ Responder spleen cells, 5 ×  l0  s of the indicated strains were cultured with GAT-M~ and 10  6 control or 
treated T  cells under Mishell-Dutton conditions. 
[[ Experiment  1: control BI0 mice were injected with B10 spleen cells as neonates; treated B10 mice were 
injected with (B 10.D2 ×  B 10)Fx spleen cells as neonates. Experiment 2: control B 10.D2 mice were injected 
with B10.D2 spleen cells as neonates; treated B10.D2 mice were injected with (B10.D2  ×  B10)F1  spleen 
cells as neonates. 
Discussion 
Mice injected within  18  h  of birth  when semiallogeneic F1 spleen cells, using a 
protocol for induction of alloantigen-specific tolerance described by Billingham et al. 
(11, 12), were not unresponsive to antigens of the allogeneic haplotype in the F1 donor. 
These  mice  rejected  skin  grafts  of the  allogeneic  haplotype with  normal  kinetics; 
spleen cells from these treated mice developed reduced but significant MLR and CTL 
responses when stimulated with the appropriate alloantigens. Spleen cells from these 
mice, however, did not develop primary in vitro PFC responses when Mq~ from the 
allogeneic  haplotype  encountered  as  neonates  were  present  in  the  culture.  This 44  HAPLOTYPE-SPECIFIC SUPPRESSOR T CELLS 
unresponsiveness was due to a population of radiosensitive haplotype-specific Ts cells 
that  were  activated  by  the  alloantigens  encountered  as  neonates.  These  Ts  cells 
nonspecifically suppressed  in vitro primary, but  not secondary, PFC responses to a 
variety of antigens and failed to suppress MLR and CTL responses. These Ts cells 
were activated by cells that shared antigens encoded by the I-A subregion of the H-2 
complex with the allogeneic parent in the F1 cells encountered neonatally. Moreover, 
syngenicity at the I-A subregion between the Ts cell and its target responding spleen 
cells was necessary and sufficient to mediate suppression. 
Active T  cell-mediated suppression  has  been  demonstrated  to regulate  immune 
responses in a variety of experimental systems. One example analogous to the findings 
reported here is the MLR suppressor system described by Rich and Rich (21,  22), in 
which a  genetically restricted population of Ts cells capable of inhibiting a primary 
MLR  was  demonstrated.  These Ts cells were stimulated  by immunizing parental 
strains of mice with  appropriate  F1 spleen cells;  4  d  later,  Ts cells were tested for 
activity in a primary MLR. We were unable to demonstrate suppression of the MLR 
under any of the conditions of our assays, unlike the suppression evident in the MLR 
suppressor system, although the mechanism of stimulation of the two types of Ts cells 
were similar. Another important difference in the two systems is the genetic constraints 
on the Ts cells.  The MLR Ts cell required syngenicity at the I-E/C subregion of the 
H-2 complex with its target cell (23), whereas the haplotype-specific Ts cell described 
here required syngenicity at the I-A subregion, both at the level of activation and at 
the effector stage. Further, the MLR Ts cell had a relatively short life span; activity 
was  maximal  4  d  after induction  but  was  not  demonstrable  by  7  d.  In  contrast, 
although the presence of haplotype-specific Ts cells has not been investigated at less 
than 8 wk after injection of F1 spleen cells, Ts cells have been demonstrated as late as 
5  mo  after  treatment,  suggesting  that  these  Ts  cells  were  a  relatively  long-lived 
population. 
These two Ts cell systems, although independent phenomena, shared some char- 
acteristics;  both are examples of Ts cells not  restricted by the I-J subregion of the 
H-2 complex, in contrast to antigen specific Ts cells (24, 25). These Ts cells, however, 
are  stimulated  and  interact  with  target  cells  in  a  genetically  restricted  manner 
controlled by the I-A subregions. It should be noted that the absence of I-J determi- 
nants  on  the  Ts  cell  has  not  been  demonstrated,  only that  syngenicity at  the  I-J 
subregion is irrelevant with respect to function. These two cell systems also demon- 
strate a phenomenon observed with some antigen-specific Ts cells, a certain degree of 
nonspecificity at the effector stage after activation (26, 27). The haplotype-specific Ts 
cell  after  activation  by  the  appropriate  stimulus  inhibits  the  primary  antibody 
responses by any spleen cells syngeneic at the I-A subregion, whereas the MLR Ts cell 
inhibits responses by any responder cell syngeneic at the I-E/C subregions (23). 
Important considerations concerning the possible mechanism(s)  of action of these 
Ts cells are the failure to inhibit T  cell responses and secondary antibody responses, 
and required presence of Ts cells during the first 36 h of culture to achieve significant 
suppression of the primary response; similar constraints have previously been reported 
for the GAT system (28). The kinetics of suppression suggest that the regulatory step 
occurs early in  the generation of the primary antibody response;  thus appropriate 
target cells may not be required or susceptible in responses by primed spleen cells or 
virgin spleen cells 48 h  or more after culture initiation. This implies that the target CRAIG M.  SORENSEN  AND  CARL W.  PIERCE  45 
cell(s), possibly an amplifier T cell, is necessary for the primary, but not the secondary, 
response and is not the same amplifier T  cell involved in the MLR; the precedent for 
such a  difference has been previously suggested (29).  Alternatively, the unprimed B 
cell may be the target cell;  further studies to determine the target cells of these Ts 
cells are in progress. 
It is important to consider some of the problems inherent in the tolerance system 
used in this study that may bear on the findings. The inability to induce tolerance by 
classical criteria is potentially disturbing, but appears to be a  function of both the 
B10  genetic background  of the  mice  used  and  the  relative  difficulty of inducing 
tolerance to antigens of the left half of the H-2 complex (13,  15, 30, 31);  higher doses 
of F1 cells administered to the neonates also failed to induce tolerance. Attempts to 
induce tolerance in neonatal BALB/c mice using (BALB/c ×  A)F1 (CAF  0  cells, thus 
eliminating the problem of the B 10 background and reducing the antigenic differences 
at H-2, have resulted in a higher incidence of tolerance by MLR and CTL responses 
and skin graft rejection but, interestingly, the phenomenon of haplotype-specific Ts 
cells as reported here were unchanged (C.  Sorensen and C. W. Pierce, unpublished 
data). More difficult observations to explain are the "partial tolerance" induced to 
the appropriate  alloantigens in MLR and CTL responses, but  the complete unre- 
sponsiveness  observed  in  antibody  responses  in  the  presence  of the  appropriate 
alloantigens. This is compounded by the observations that the Ts cells responsible for 
lack of antibody responses are unable to suppress  MLR and CTL responses. This 
paradox is under investigation. 
A final point concerns the potential mechanism of action of these Ts cells. Most Ts 
cell  systems described  to  date  involve  a  soluble  mediator;  this  system  is  not  an 
exception.  The  demonstration  and  characterization  of a  soluble  factor  mediating 
haplotype-specific suppression is the subject of the accompanying report (32). 
Summary 
C57BL/10 mice were injected with semiallogeneic (B10.D2 X C57BL/10)F1 spleen 
cells via the anterior facial vein within 24 h of birth to induce tolerance to B10.D2 
(H-2  d)  alloantigens. Spleen cells from these mice as adults developed reduced, but 
significant, mixed lymphocyte and cytotoxic lymphocyte responses in vitro to H-2  d 
stimulator cells and these treated mice rejected first-set B10.D2 skin grafts within a 
normal time-course, indicating that at best only a state of partial tolerance had been 
induced. Spleen cells from these mice failed to develop antibody responses to a variety 
of antigens in vitro when H-2  d macrophages were in the cultures. Partially purified T 
cells from these neonatally treated mice suppressed primary antibody responses by 
normal  syngeneic  spleen  cells  in  the  presence  of H-2  d  but  not  other  allogeneic 
macrophages. These radiosensitive, haplotype-specific suppressor T  (Ts) cells inhibited 
primary  antibody responses  by  blocking  initiation  of the  response,  but  failed  to 
suppress secondary antibody responses and mixed lymphocyte  or cytotoxic lymphocyte 
responses by appropriate responding spleen cells. To activate H-2  d haplotype-specific 
Ts  cells,  stimulation with  LA  d subregion  antigen(s)  was  necessary and  sufficient; 
syngenicity at  the I-A subregion of H-2  between the activated Ts cells and target 
responding  spleen  cell  populations  was  also  necessary  and  sufficient  to  achieve 
suppression. Comparable results have been obtained with spleen cells from BALB/c 
mice  injected  as  neonates  with  (B10.D2  ×  C57BL/10)F1  spleen  cells  where  LA  b 46  HAPLOTYPE-SPECIFIC  SUPPRESSOR  T  CELLS 
antigens  activate the haplotype-specific Ts cells.  Implications for the significance of 
this population of haplotype-specific Ts cells in immune regulation are discussed and 
the  properties  of these  Ts  cells  are  compared  and  contrasted  with  other  antigen- 
specific and nonspecific Ts cells whose activity is restricted by I-region products. 
We  thank  Dr. Judy  Kapp  for helpful  discussions,  Drs.  D.  Shreffler  and J.  Stimplfing  for 
providing mice, and Ms. Barbara Wollberg for preparation of this manuscript. 
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